Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation

Xarelto® on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation

The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and systemic embolism (Stroke Prevention in Atrial Fibrillation) will be observed.

The study takes place in Korea and Taiwan. Approximately a total of 1200 patients will be included in the study within 12 months. The observation period for each patient is 1 year from enrollment into the study, or until withdrawal of consent or lost to follow-up. Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions.

Inclusion Criteria:

• Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan)
• Diagnosis of NVAF
• Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician's routine treatment practice
• Treatment naïve regarding stroke prevention for atrial fibrillation
• Signed informed consent

Exclusion Criteria:

• Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC)
• Patients participating in an investigational program with interventions outside of routine clinical practice